Biotech entity

Mounjaro (tirzepatide)

Product

Mounjaro (tirzepatide) is most often covered alongside Anti-Diabetic Segment, which appears in 1 of these 2 stories. Across a 20-day span, the pace is roughly 0.7 stories per week. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category.

Last mentioned: Aug 9, 2026

RSS updates
Share

Entity pulse

Recent coverage · Mounjaro (tirzepatide)

↑
2 stories
6 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Mounjaro (tirzepatide)

Mounjaro (tirzepatide) is most often covered alongside Anti-Diabetic Segment, which appears in 1 of these 2 stories. Across a 20-day span, the pace is roughly 0.7 stories per week. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. Source depth averages 2.5 original sources per story, versus 2.3 across the same-window beat baseline. This profile follows 2 Biotech stories mentioning Mounjaro (tirzepatide) across the period from July 21, 2026 to August 9, 2026.

Stories tracked
2
Per week
0.7
Sources per story
2.5

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 132 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Mounjaro (tirzepatide). Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Lawsuit Filed

    Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.

  2. FDA Approves Wegovy 7.2 mg

    Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.

Stories mentioning Mounjaro (tirzepatide) 2

Pharma Neutral

Oncology, diabetes drive Indian pharma; Mounjaro sales up 880% to ₹1,228 Cr

The Indian pharmaceutical market expanded 12.1% by value in July 2026, but unit growth inched up only 1.6%, revealing a market shifting to high-value, specialty therapies. Anti-neoplastics and anti-diabetics led therapy-area growth, while Eli Lilly’s Mounjaro captured more than half of the diabetes segment with an 880% sales surge. For biotech and pharma firms, the data underscores the imperative to invest in innovation and patient access strategies.

2 sources

Source: aninews.in · bignewsnetwork.com

Mounjaro (tirzepatide) is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.